Prevalence of antibodies. Data are n (%), unless otherwise indicated.
| jSLE, n = 216 | aSLE, n = 719 | p | OR (aSLE/jSLE) | 95% CI | |
|---|---|---|---|---|---|
| ANA | 211 (98) | 695 (97) | 0.134 | 2.452 | 0.731–8.222 |
| Anti-dsDNA | 170 (78.7) | 500 (69.5) | 0.009 | 1.619 | 1.127–2.326 |
| Anti-Sm | 22 (10.2) | 141 (19.6) | 0.001 | 0.465 | 0.288–0.750 |
| Anti-RNP | 13 (6) | 118 (16) | < 0.001 | 0.326 | 0.180–0.591 |
| Anti-Ro | 23 (10.6) | 184 (25) | < 0.001 | 0.347 | 0.218–0.551 |
| Anti-La | 11 (5.1) | 81 (11.3) | 0.008 | 0.423 | 0.221–0.809 |
| aCL IgG | 69 (31.9) | 151 (21) | 0.001 | 1.766 | 1.260–2.475 |
| aCL IgM | 79 (36.6) | 139 (19.3) | < 0.001 | 2.406 | 1.725–3.357 |
| LA | 17 (7.9) | 77 (10.7) | 0.231 | 0.716 | 0.413–1.239 |
aCL: anticardiolipin; LA: lupus anticoagulant; jSLE: juvenile-onset systemic lupus erythematosus; aSLE: adult-onset SLE; ANA: antinuclear antibody.